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Abstract
Aims/hypothesis The glomerular endothelial layer is coated
by the endothelial surface layer (ESL), which is suggested
to play a role in regulation of the permselectivity of
macromolecules. Production of heparanase, a degrading
enzyme of the ESL, is induced by reactive oxygen species
(ROS). We hypothesised that oxidative stress could cause
deterioration of the glomerular ESL by induction of
heparanase, resulting in increased glomerular permeability.
Methods Male Zucker fatty (ZF) rats with albuminuria and
Zucker lean (ZL) rats were used in this study. Some of the
ZF rats were treated with the angiotensin II receptor
blocker, irbesartan. We determined the amount of ESL by
wheat germ agglutinin staining and heparan sulphate
proteoglycan production by western blot analysis. Glomer-
ular hyperfiltration of macromolecules was visualised using
in vivo microscopy. We used 2′,7′-dichlorofluorescein
diacetate-derived chemiluminescence staining to assess
ROS production, and heparanase production and expression
were determined by western blot analysis and quantitative
real-time polymerase chain reaction respectively.
Results By 18 weeks of age, ZF rats had developed
albuminuria. The glomerular endothelial cell glycocalyx
was significantly decreased in ZF compared with ZL rats.
Glomerular filtration and the permeability of macromole-
cules were increased in ZF, but not in ZL rats. Glomerular
ROS and heparanase production were significantly in-
creased in ZF compared with ZL rats. These changes in
ZF rats were reversed by irbesartan treatment.
Conclusions/interpretation Increased oxidative stress indu-
ces glomerular ESL deterioration in part through increased
heparanase levels, resulting in exacerbation of glomerular
permselectivity and development of albuminuria.
Keywords Endothelial cell.Endothelial surface layer.
Glomerulus.Glycocalyx.Haemodynamics.Permeability.
Reactive oxygen species.Vascular regulation.Zucker fatty
rat
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Recent clinical studies have indicated that a decreased
glomerular filtration rate and albuminuria are strong risk
factors not only for end-stage renal disease, but also
cardiovascular events including coronary heart disease,
heart failure, stroke and peripheral arterial disease [1, 2].
An elevated urinary albumin excretion rate is associated
with a two- to fourfold increase in cardiovascular and all-
cause mortality rates [3]. These observations have led to the
hypothesis that a common process underlies albuminuria
and cardiovascular events. Any degree of albuminuria is
thought to increase the risk of cardiovascular events in the
general population with or without diabetes or hypertension
[4, 5]. The risk of cardiovascular events increases with an
increase in urine albumin:creatinine ratio, starting well
below the microalbuminuria cut-off [4, 5]. The results of a
clinical study have shown that endothelial dysfunction is
correlated with albuminuria [6], suggesting that endothelial
dysfunction may be a link between albuminuria and
atherosclerotic cardiovascular disease. However, the de-
tailed mechanisms linking microalbuminuria with end-
organ damage remain unclear.
Microalbuminuria results from the increased passage of
albumin through the glomerular filtration barrier. This barrier
is composed of glomerular endothelial cells (GEnCs), a
glomerular basement membrane and glomerular epithelial
cells.IthasbeenthoughtthatGEnCsdonothaveanimportant
role in the filtration barrier because of the many small pores,
known as fenestrae, which are 60 to 80 nm in diameter [7]. It
has recently been reported that GEnCs are covered by an
endothelial surface layer (ESL), containing glycocalyx and
cell coat [7], which extends into the fenestrae [8]. The ESL
covers the cellular surface and is composed of large amounts
of glycoprotein, such as heparan sulphate proteoglycan
(HSPG) [9]. Because of the presence of sulphated sugar
chains in HSPG, the ESL is highly negatively charged,
thereby regulates vascular permeability. A decrease in the
thickness of the ESL is associated with an increase in
vascular permeability [10] and the onset of albuminuria [11].
Furthermore, decreased ESL thickness was found to increase
the GEnC permeability in an vitro study [8]. However, the
relationship between glomerular endothelial dysfunction,
perturbation of the ESL and the appearance of albuminuria
in vivo remains to be elucidated.
We hypothesised that the glomerular ESL contributes to
regulation of glomerular permeability and the development
of albuminuria. Using the diabetic Zucker fatty (ZF) rat as a
model of metabolic syndrome, we therefore investigated the
relationship between perturbation of the ESL and develop-
ment of albuminuria, as well as the molecular mechanisms
involved and the influence of the angiotensin II receptor
blocker (ARB), irbesartan.
Methods
In vivo study: animals Male Zucker lean (ZL) and ZF rats
(6 weeks old) were purchased from Charles River Labora-
tories Japan (Kanagawa, Japan). Obese rats weighing 140
to 150 g were randomly divided into two groups: ZF rats
treated with vehicle (n=8) or those treated with irbesartan
(ZF+ARB, n=8, 25 mg kg
−1 day
−1; Dainippon Sumitomo
Pharma, Osaka, Japan). ZL rats weighing 100 to 110 g were
treated with vehicle (n=8). All rats were kept under
controlled temperature and humidity conditions with 12 h
light/dark cycles and had free access to water. The
experimental protocol (number 08-007) was approved by
the Animal Research Committee of Kawasaki Medical
School and was conducted according to the Guide for the
Care and Use of Laboratory Animals of Kawasaki Medical
School based on the National Institutes of Health Guide for
the Care and Use of Laboratory Animals (NIH Publications
No. 80-23, revised 1996).
Physiological and biochemical measurements At 12 weeks
after the start of treatment, systolic arterial blood pressure
was measured in pre-warmed rats using the tail-cuff method
(BP-98A; Softron, Tokyo, Japan). Glucose tolerance was
assessed by intraperitoneal glucose tolerance test after
fasting for 16 h. A bolus of glucose (2 g/kg i.p.) was
injected and blood samples were collected from the tail vein
at intervals of 0 and 120 min, and tested for glucose.
Glucose was measured using a glucose meter (Medisafe-
Mini; Terumo, Tokyo, Japan). To collect urine samples at
12 weeks, rats were placed in metabolism cages for 24 h
and given access to tap water, but no food. Albumin
concentration in 24 h urine samples was measured by
enzyme-linked immunosorbent assay (Exocell, Philadel-
phia, PA, USA). After collection of urine, the rats were
killed under sevoflurane inhalation anaesthesia and blood
samples were obtained immediately. Serum creatinine and
fasting serum glucose levels were measured.
Histological assessment Kidney sections (4 μm thick) were
stained with periodic acid–Schiff’s (PAS) and tetramethyl
rhodamine isothiocyanate-conjugated wheat germ agglutinin
(WGA) (Vector Laboratories, Burlingame, CA, USA). PAS-
stainedkidneysectionswerephotographedusingamicroscope
(Eclipse E800; Nikon, Tokyo, Japan) and digitised into 1,372-
to 1,024-pixel colour scale images using a software program
(ACT-1C DXM 1200C; Nikon). Histological scores were
assessed using a Coolscope (Nikon). Tetramethylrhodamine
isothiocyanate-conjugated WGA-stainedkidneysections were
analysed using TCS-NT system software (Leica-Microsys-
tems, Tokyo Japan). Three nephrologists semiquantitatively
analysed PAS- and WGA-stained sections in a blind fashion.
The severity of glomerular injury was evaluated by glomer-
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The glomerular ESL was also evaluated by the WGA
staining score with respect to the amount of degradation as
follows: 0, none; 1, mild; 2, moderate; 3, severe; 4, global
degradation. At least 50 glomeruli were randomly selected
from each rat and the mean score was calculated.
Lanthanum nitrate staining Lanthanum nitrate staining was
performed as described previously [13]. A 5 ml bolus of
lanthanum nitrate solution (1.0%, wt/vol., pH 7.1) was
injected into the aorta. Fixed tissues were embedded in
Spurr’s low-viscosity resin (Electron Microscopy Sciences,
Hatfield, PA, USA) and polymerised. They were then cut
with a diamond knife on an Ultracut UCT microtome
(Leica-Microsystems), mounted on copper grids coated
with Formvar films and stained with uranyl acetate and
lead citrate. Ultrathin sections were examined with an
electron microscope (H-7100; Hitachi, Tokyo, Japan).
In vivo imaging of macromolecule hyperfiltration For
fluorescent probes, 40 kDa fluorescein–dextran (anionic,
excitation 494 nm, emission 518 nm) was obtained from
Invitrogen (Tokyo, Japan). A multiphoton excitation laser-
scanning fluorescence microscopy confocal microscope
system (TCS SP2 AOBS MP; Leica-Microsystems) was
used in these studies. In vivo imaging of the glomerular
microcirculation was performed as described previously
[14]. For analysis of glomerular permeability, a 40 kDa
fluorescein–dextran solution was infused through the
jugular venous catheter immediately.
In vitro study: cells Primary normal human GEnCs were
purchased from Cell System (Kirkland, WA, USA) and
cultured according to the manufacturer’s instructions.
Human GEnCs were cultured in endothelial cell basal
medium-2 (Lonza, Walkersville, MD, USA) containing v/v
2% fetal bovine serum under humidified conditions (95%
air, 5% CO2) at 37°C. Confluent cells from seven to ten
passages were used in the experiments. These cells were
divided into three groups: LG, low glucose (5 mmol/l); HG,
high glucose (30 mmol/l); and HG+ARB, high glucose
plus irbesartan (5 µmol/l). The cells were incubated at 37°C
for 2 to 24 h (2 h for reactive oxygen species [ROS]
detection and NAD(P)H oxidase assay, 4 h for RNA
isolation and nuclear protein preparation, and 24 h for total
protein preparation).
Fluorescence spectrometric assay for production of ROS
Glomeruli were isolated by sieving as previously described
[15]. Production of ROS, including H2O2 and peroxynitrite,
was measured in isolated glomeruli using the 2′,7′-dichlor-
odihydrofluorescein-diacetate (DCFH-DA) method, as pre-
viously described [15]. The mean fluorescence intensity of
the isolated glomeruli (600 glomeruli from six rats in each
group) was analysed using TCS-NT system software
(Leica-Microsystems). Intracellular ROS levels were mea-
sured using fluorescence-activated cell sorting [16]. Cells
were incubated for 15 min with 20 μmol/l DCFH-DA in
medium at 37°C in the dark. In each sample, a minimum of
10,000 cells was subjected to fluorescence-activated cell
sorting using a FACS Calibur (Nippon Becton Dickinson,
Tokyo, Japan) and CellQuest software (Nippon Becton
Dickinson).
Lucigenin chemiluminescence assay for NAD(P)H oxidase
activity Superoxide production by NAD(P)H oxidase in
isolated glomeruli or cultured cells was measured by
lucigenin chemiluminescence as described previously [17].
Lucigenin chemiluminescence was expressed in units
min
−1 mg
−1.
RNA isolation and real-time quantitative polymerase chain
reaction Total RNA extraction from isolated glomeruli or
cultured cells, reverse transcriptase reaction and real-time
quantitative polymerase chain reaction were performed as
described previously [17]. The primers and probes used for
rat gp91phox (also known as Cybb), rat p67phox, rat
heparanase and human heparanase were listed in Electronic
supplementary material [ESM] Table 1.
Western blotting Extraction of total cellular protein and
nuclear protein was performed using extraction reagent (T-
PER tissue protein extraction reagent, NE-PER nuclear and
cytoplasmic extraction kit; Thermo Fisher Scientific, Rock-
ford, IL, USA) according to the manufacturer’s instructions.
Sodium dodecyl sulphate–polyacrylamide gel electrophore-
sis was performed on portions of the isolated glomeruli
(100 μg/lane) or cultured cells (20 μg/lane for heparanase-
1, 5 μg/lane for v-ets erythroblastosis virus E26 oncogene
homologue 1 [avian] [ETS-1]). Anti-perlecan antibody
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-
syndecan-1 antibody (Santa Cruz), anti-heparanase-1 anti-
body (Santa Cruz), anti-ETS-1 antibody (Abcam, Cambridge,
MA, USA), anti-tubulin alpha antibody (Lab vision, Thermo
Scientific, CA, USA) and anti-beta tubulin antibody (Santa
Cruz) were used as the primary antibodies. Coomassie
Brilliant Blue staining of the membrane confirmed equal
loading and transfer. Signals were detected using the ECL
system (Amersham Biosciences, Piscataway, NJ, USA). The
relativeopticaldensitiesofbandswerequantifiedusingImage
J analysis software V1.42 (http://rsbweb.nih.gov/ij//, accessed
1 January 2010).
Statistical analysis Values are expressed as mean ± SD. All
variables except the glomerular damage score and WGA
staining score were evaluated with two-tailed unpaired
2058 Diabetologia (2010) 53:2056–2065Student’s t test or Welch’s t test. The glomerular damage
score and WGA staining score were evaluated with Mann–
Whitney’s U test. A p value of p<0.05 denoted a
statistically significant difference.
Results
Physiological data and glomerular injury in ZF rats
Table 1 shows physiological data for the three groups.
There were statistically significant increases in body
weight, glucose-loaded serum glucose level and albumin-
uria, and a decrease in serum creatinine levels in the ZF
vehicle compared with the ZL rat groups. In contrast,
administration of irbesartan (ZF+ARB) led to significant
decreases in body weight, systolic blood pressure and
albuminuria compared with the ZF vehicle group, but had
no effect on glucose-loaded serum glucose level. Glomer-
ular injury was evaluated by glomerulosclerosis score with
PAS staining in all groups (Fig. 1). There was a slight
expansion of the mesangial area in the ZF compared with
the ZL animals (glomerulosclerosis score 1.0±0.5 vs 0.5±
0.5, respectively, p<0.05). ARB administration did not
affect the glomerulosclerosis score. The grading scores,
however, remained low in all three groups, because the
histological changes were unremarkable even in untreated
ZF rats.
Evaluation of glomerular ESL First, glomerular ESL was
detected by lectin staining. Paraffin-embedded specimens
were stained with WGA lectin, which binds to sugar
residues, sialic acid and N-acetylglucosaminyl residues of
glycoproteins. WGA lectin was observed on the glomerular
loop including endothelial cells, podocytes and the glomer-
ular basement membrane in ZL rats (Fig. 2a). The disarray
of WGA staining was demonstrated in ZF vehicle-treated
rats (Fig. 2b), but was significantly ameliorated by
treatment with irbesartan (Fig. 2c). The degree of WGA
disarray was examined semi-quantitatively using a scoring
system (Fig. 2i). The score was significantly increased in
ZF vehicle-treated compared with the ZL rats (2.5±0.7 vs
1.8±0.3, respectively, p<0.05) and ameliorated by irbesar-
tan treatment (2.1±0.5, p<0.05 vs ZF vehicle). Second, the
glomerular ESL was evaluated using the lanthanum nitrate
perfusion method. To delineate the glomerular ESL by
electron microscopy, we perfused the kidneys with the
cationic reagent lanthanum nitrate, which is commonly
used as an efficient marker of anionic sites on the ESL. In
the ZL rats, deposits of lanthanum nitrate were found on the
surface of endothelial cells and podocytes (Fig. 2d).
However, in the ZF vehicle-treated rats, lanthanum nitrate
deposits were only observed on the surface of the
podocytes (Fig. 2e). In the ZF+ARB group, the deposits
were observed again on the surface of endothelial cells
(Fig. 2f). Third, the amount of proteoglycan core proteins
was examined by western blot analysis using lysates from
isolated glomeruli. Perlecan (a cross-linked extracellular
matrix molecule) and syndecan (which is cell membrane-
bound) are HSPGs, which are major components of the
glycocalyx [18]. Perlecan levels were not changed in any of
the groups (Fig. 2g), but syndecan levels were significantly
reduced in the ZF vehicle-treated compared with the ZL
animals (0.7±0.1-fold, p<0.05 vs ZL). The reduction was
ameliorated by administration of irbesartan (p<0.05 vs ZF
vehicle).
Visualisation of glomerular hyperfiltration of macromolecules
Glomerular hyperfiltration of macromolecules was exam-
ined by intravenous injection of fluorescein isothiocyanate-
conjugated dextran as previously reported [14]. We used
40 kDa dextran, which is not easily filtrated in ESL-
preserved endothelium, to visualise glomerular filtration in
all groups. There was a very small volume of filtered
40 kDa fluorescein isothiocyanate-labelled dextran in the
Bowman’s capsule space in the ZL group (Fig. 3,E S M
Video clip 1), but massive leakage of this dextran was seen
in ZF vehicle-treated animals (Fig. 3, ESM Video clip 2).
Only a small amount of 40 kDa dextran was observed in
the glomeruli of the ZF+ARB rats (Fig. 3,E S MV i d e o
clip 3).
Evaluation of heparanase expression and ROS production
In the ZF vehicle-treated rats, heparanase protein levels
were significantly increased compared with the ZL group
(p<0.05) (Fig. 4a). ARB administration significantly
Characteristics ZL (n=6) ZF vehicle (n=8) ZF+ARB (n=8)
Body weight (g) 381±21 691±32
a 594±47
a,b
Systolic BP (mmHg) 128±5 122±17 104±7
a,b
FSG (mmol/l) 4.2±0.7 4.2±1.7 3.6±1.6
Glucose-loaded SG (mmol/l) 7.7±1.4 10.9±2.4
a 9.9±1.7
a
S-Crn (µmol/l) 19.5±5.3 13.3±2.7
a 12.4±3.5
a
ACR (mg/mmol) 23.6±13.1 288.5±26.2
a 65.6±7.9
b
Table 1 Physiological data
Data are expressed as
mean ± SD
ap<0.05 vs ZL;
bp<0.05 vs ZF
vehicle
ACR, urinary albumin:creati-
nine ratio; FSG, fasting serum
glucose; S-Crn, serum creati-
nine; SG, serum glucose
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tion of heparanase has been shown to be regulated by
oxidative stress [19]. Therefore, ROS production in glomer-
uli was evaluated by confocal laser-scanning microscopy
using DCFH-DA staining. The glomerular 2′,7 ′-dichloro-
fluorescein intensity was increased in ZF vehicle-treated
compared with ZL rats (1.9±0.9-fold, p<0.05) and reduced
by ARB treatment (1.4±0.7-fold, p<0.05 vs ZF vehicle).
NAD(P)H oxidase activity in isolated glomeruli as a source
of ROS production was determined by lucigenin chemilu-
minescence assay (Fig. 4b). ROS production by NAD(P)H
oxidase was significantly increased in the ZF vehicle-treated
compared with the ZL rats (p<0.05), while irbesartan
treatment significantly reduced NAD(P)H oxidase activity
(p<0 . 0 5v sZ Fv e h i c l e ) .T h em R N Ae x p r e s s i o no ft h eN A D
(P)H oxidase component genes gp91phox and p67phox were
increased in the ZF vehicle-treated compared with the ZL
rats (Fig. 4c, d). These changes were ameliorated by
administration of irbesartan.
Mechanisms of heparanase induction in glomerular endo-
thelial cells The rate of ROS production was increased in
the human GEnCs treated with high glucose compared with
those treated with low glucose. ROS production in the
ARB-treated group was reduced to the same level as in the
low glucose-treated group (Fig. 5a). NAD(P)H oxidase
activity assessed by lucigenin chemiluminescence was
enhanced in the high glucose compared with the low
glucose and was ameliorated in the high glucose+ARB
group (Fig. 5b). The expression of heparanase mRNA and
heparanase protein levels were also increased in the human
GEnCs by high glucose treatment (Fig. 5c, d), these
increases being normalised by co-incubation with irbesar-
tan. ETS-1 is one of the key transcription factors that
regulate heparanase gene expression [20]. Protein levels of
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2060 Diabetologia (2010) 53:2056–2065ETS-1 in the nuclei of human GEnCs were also increased
by high glucose treatment and restored by co-treatment
with irbesartan (Fig. 5e).
Discussion
The aim of this study was to examine whether the
glomerular ESL contributes to regulation of glomerular
permeability and the development of albuminuria. We have
shown that glomerular ESL perturbation coincides with
increased glomerular vascular permeability and albuminuria
in a rat model of metabolic syndrome. We also found that
the increased ROS production in GEnCs upregulated
expression of heparanase, an endoglycosidase that degrades
HSPG, a major constituent of the vascular glycocalyx.
Furthermore, we found that irbesartan treatment ameliorat-
ed oxidative stress, preserved the integrity of the glomerular
ESL and also exerted an antiproteinuric effect.
The ESL covers the systemic vascular endothelium and
coats the luminal surface of the glomerular capillaries.
Previous studies have indicated that the glycocalyx, a
component of the ESL, regulates vascular permeability
[10], senses shear stress as a mechano-transduction sensor
[21], attaches to blood cells [22], regulates enzyme activity
[23, 24] and anchors enzymes to the cell surface [25].
However, the role of the glomerular ESL remains poorly
defined. Recently, Singh et al. reported that enzymatic
removal of glycocalyx from GEnCs leads to increased
permeability of albumin across the cell layer [8]. Reduction
of the glomerular endothelial glycocalyx was detected and
demonstrated to be involved in deterioration of permselec-
tivity in an adriamycin-induced rat model of nephrotic
syndrome [26]. In the present study, we revealed that the
glomerular ESL is decreased in ZF rats as visualised by
WGA and lanthanum nitrate staining methods. Further-
more, the results of lanthanum nitrate staining indicated that
the ESL on the epithelial side along the glomerular
basement membrane was well preserved, although the
ESL is significantly decreased in this disease model. These
results suggest a causal relationship between decreased
glomerular ESL and enhanced glomerular permeability of
macromolecules in vivo.
Podocyte slit diaphragm also plays an important role in
glomerular permeability. Previous studies have reported
that injured podocytes with foot process effacements
developed a large degree of proteinuria [27]. On the other
hand, albuminuria can be observed without podocyte foot
process effacement in some disease models. Injection of
antibodies to vascular endothelial growth factor or soluble
vascular endothelial growth factor receptor 1 [28] cause
albuminuria, hypertension and endothelial cell dysfunction
without affecting podocyte morphology. These data indicate
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Diabetologia (2010) 53:2056–2065 2061that GEnCs may play a role in the successful retention of
albumin. Disruption of slit diaphragms, as in nephrin-
knockout mice, causes massive proteinuria, with not a small
degree of albuminuria [29].
At present, it is not clear whether glomerular permeability
isdependentonESLthicknessorachangeinESLquality.van
den Hoven et al. reported that reduction of anionic sites did
not lead to proteinuria in heparanase-overexpressed mice, but
these mice had a mild but significant increase in urinary
albumin excretion [30]. Also perlecan-deficient mice did not
develop glomerular abnormalities and albuminuria under
physiological conditions [31], but did develop albuminuria
under albumin-loaded conditions. These studies suggest that
even if one of the HSPGs did decrease in physiological
conditions, it might not be enough to develop morphological
changes or proteinuria. We have demonstrated that syndecan,
one of the glomerular HSPGs, decreased in ZF rat. However,
we were unable to exclude the possibility that other
components of glomerular ESL were altered. We speculate
that quantitative and qualitative alterations of ESL developed
in this model and resulted in perturbation of glomerular
permeability.
We observed that heparanase expression was stimulated
in the glomeruli of ZF rats. HSPG confers anionic charge to
the glomerular vascular wall so that the ESL regulates
permselectivity of the glomerulus [10]. HSPG is initially
internalised from the cell surface mainly by endocytosis
[32]. Glycosaminoglycan chains are degraded by hepar-
anase, an endo-β-D-glucuronidase that specifically reacts
with heparan sulphate. Increased levels of heparanase and a
concomitant decrease in glomerular heparan sulphate
glycosaminoglycan have been demonstrated in a variety
of disease models, including streptozotocin-induced
diabetes, adriamycin-induced nephrotic syndrome and
Heymann’s nephritis [19, 33, 34]. Decreased levels of
glomerular heparan sulphate have also been demonstrated
in human renal diseases, including diabetic nephropathy
[35], but levels are minimally changed in nephritic
syndrome [36]. Moreover, it has been reported that
heparanase, which degrades the glycocalyx, is regulated
by high glucose [37], angiotensin II and ROS [19]. The
results of the present study also demonstrated the upregu-
lation of heparanase by high glucose concentration and the
simultaneous decrease in glycocalyx, a major component of
ESL.
Sulphated portions of glycosaminoglycan side chains in
HSPG play an important role in charge-dependent selectiv-
ity of glomerular filtration of plasma proteins. N-deacety-
lase/N-sulfotransferase (NDST [also known as NDST1]),
which substitutes the N-acetyl moiety of glucosamine for a
sulphate group, is the key enzyme regulating sulphation of
glycosaminoglycan chains. Williams et al. have reported
that hepatic NDST mRNA, NDST protein and enzymatic
activities were suppressed in a rat model of diabetes and
suggested that angiotensin II contributes to the suppression
of NDST protein and enzymatic activity [38]. We also
examined glomerular expression of NDST and confirmed
that expression was decreased in the ZF group compared
with ZL group and that ARB treatment increased NDST
expression (data not shown). Using another model of renal
nephritis, Nakayama et al. reported that NDST mRNA is
decreased in glomeruli during the nephritic period [39].
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Fig. 5 High-glucose-induced ROS production, NAD(P)H oxidase
activity and heparanase expression in human GEnCs. a Evaluation of
ROS production by flow cytometry in DCFH-stained cells. White, low
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2062 Diabetologia (2010) 53:2056–2065These data suggest an important role for this enzyme in
heparan sulphate assembly in GEnCs and in the pathogen-
esis of albuminuria.
IthasbeenreportedthatACEinhibitorsandARBssuppress
heparanase expression and preserve HSPGs from degradation
[19, 40]. Similar effects were achieved by antioxidant
administration, suggesting that the antioxidant activities of
ACE inhibitors and ARBs are involved in the protection of
HSPGs. Angiotensin II is known to directly induce expres-
sion of NAD(P)H oxidase components and enhance ROS
generation [41]. The results of the present study demonstrated
that irbesartan suppresses NAD(P)H oxidase activation and
possesses antioxidant activity. ARBs are multifunctional
agents, which effectively reduce blood nitrotyrosine levels
in patients with type 1 diabetes [42] and restore impaired
catalase and glutathione peroxidase activities [43, 44]. The
ability of irbesartan to decrease ROS production and activate
the antioxidant defence system could prevent upregulation of
heparanase in this rat model of metabolic syndrome.
Blood pressure was significantly decreased by irbesartan
treatment in ZF rats. Thus, the hypotensive effect of
irbesartan would affect glomerular hypertension and glo-
merular permeability. We have previously reported that
intra-glomerular hypertension induces glomerular ROS
production that is dependent on NAD(P)H oxidase activity
[15]. ARB treatment improves glomerular hypertension
through dilation of efferent arterioles and reduction of
oxidative stress in glomeruli. In this study, irbesartan may
have improved glomerular permeability by reducing ROS
production in a way that was dependent on and independent
of the intra-glomerular pressure-lowering effect.
The glycocalyx is ubiquitously distributed on vascular
endothelial cells throughout the body. A series of animal
studies revealed that disruption of the glycocalyx was
associated with vascular disease such as adhesion of
inflammatory cells to the vessel wall and hypertrophy of the
vascular wall [45]. The glycocalyx also serves as a
mechanosensor, sensing vascular shear stress to regulate
vascular tone by nitric oxide generation [21]. Taken together,
these results suggest that impairment of the ESL can affect
vascular function and may be the first sign of vascular
disorders. A correlation between acute hyperglycaemia and
the onset of cardiovascular events has been shown by a
large-scale clinical study [46]. Considering that the levels of
glycocalyx decrease upon a rapid increase in blood sugar
level [47], deterioration of the ESL is likely to be a risk
factor for cardiovascular disease. The results of a separate
clinical study demonstrated that albuminuria is indicative of
systemic endothelial dysfunction in diabetes mellitus [6],
whereas the Hoorn study showed that microalbuminuria
correlates with the degree of impairment of flow-mediated
dilation, which is indicative of vascular endothelial dysfunc-
tion in diabetic and non-diabetic patients [48]. This strongly
suggests that deterioration of the ESL induces endothelial
dysfunction and that such deterioration in the kidney leads to
the onset of albuminuria.
We demonstrated an association between the deterioration
of the ESL and albuminuria, an established surrogate marker
of cardiovascular events. A limitation of the present study is
that we were not able to determine the mechanism of this
association. Studies using endothelial cell-specific transgenic
mice that are deficient in or overexpress heparanase and/or
NDST will elucidate the effects of these enzymes on
glycocalyx production in the glomerular endothelium and
any role of the ESL in the development of albuminuria.
Another limitation of this study is that the ZF rat is a model of
obesity and metabolic syndrome, not of diabetic nephropathy.
The ZF rat shows postprandial hyperglycaemia and presents
albuminuria, not proteinuria; it therefore resembles an early
stage of diabetic nephropathy with microalbuminuria in
humans. Thus, the results of the present study cannot apply
to all stages of diabetic nephropathy.
In conclusion, we have demonstrated that the glomerular
ESL is implicated in regulation of glomerular wall
permeability and that ROS-induced deterioration of the
ESL exacerbates glomerular permeability. The ARB irbe-
sartan prevented deterioration of the ESL and suppressed
albuminuria. It is highly likely that protection of the ESL
would not only be effective in suppressing development of
albuminuria, but also in slowing the progression of
atherosclerosis. Therefore, the ESL is a potential therapeu-
tic target for cardiovascular diseases.
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